First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 86
Biopharm R&D efforts reflect Novo Nordisk's commitment
to satisfy unmet patient needs
Aim to develop subcutaneous haemophilia
products and long-acting growth hormone
Novo Nordisk Biopharm portfolio
Pursue leadership in
HAEMOPHILIA
Strengthen
leadership in
GROWTH
DISORDERS
Pursue bolt-on
opportunities
Pursue subcutaneous delivery
of long-acting coagulation
factors and bypassing agents
Bring long-acting growth
hormone somapacitan to
market and expand indications
Identify bolt-on acquisition or
in-licensing opportunities in
adjacent disease area
changing
diabetes®
Haemophilia
Growth hormone
Research/
preclinical
Phase 1/2
N8-GP sc
concizumab
Phase 3
N8-GP IV
somapacitan¹
NovoEight®
Refixia®
NovoThirteenⓇ
Approved/
Launched
Norditropin®
NovoSevenⓇ
1 Somapacitan is currently in phase 3 for adult growth hormone deficiency and phase 2 for
growth hormone deficiency in children
Note: NovoThirteenⓇ and Refixia® are the brand names in the majority of countries,
whereas these products are marketed as TRETTENⓇ and RebinynⓇ respectively in the US
sc: Subcutaneous; IV: Intravenous
novo nordiskView entire presentation